Demonty Gaston, Bernard-Marty Chantal, Puglisi Fabio, Mancini Isabelle, Piccart Martine
Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium.
Eur J Cancer. 2007 Feb;43(3):497-509. doi: 10.1016/j.ejca.2006.10.020. Epub 2007 Jan 12.
The aim of this review article is to examine the available evidence regarding diagnosis and treatment of HER-2 positive breast cancer. This group of breast tumours (up to 30% of the total number of breast cancers) is known for having a more aggressive behaviour. The current recommendations for HER-2 positive tumour diagnosis are discussed since accurate identification of HER-2 amplification or overexpression is key for allowing a correct risk assessment and treatment. HER-2 positive tumours can be treated with trastuzumab (Herceptin, Hoffmann-La Roche, Basel, Switzerland), a monoclonal antibody targeted against the HER-2 receptor. The role of this drug in the metastatic, adjuvant and neoadjuvant setting is reviewed. The results of the recently reported adjuvant trials are commented, as the positive results of these trials changed the standard of care for patients with this particular type of breast cancer.
这篇综述文章的目的是审视关于HER-2阳性乳腺癌诊断与治疗的现有证据。这组乳腺肿瘤（占乳腺癌总数的30%）以具有更侵袭性的行为而闻名。由于准确识别HER-2扩增或过表达是进行正确风险评估和治疗的关键，因此讨论了当前HER-2阳性肿瘤的诊断建议。HER-2阳性肿瘤可用曲妥珠单抗（赫赛汀，瑞士巴塞尔霍夫曼-罗氏公司）治疗，这是一种针对HER-2受体的单克隆抗体。本文回顾了该药物在转移性、辅助性和新辅助治疗中的作用。对最近报道的辅助治疗试验结果进行了评论，因为这些试验的阳性结果改变了这类特殊乳腺癌患者的护理标准。
